# Adamadle

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adamadle

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.adamadle.cn
- Total disclosed funding: $341M
- Latest round: Series B (Dec 28, 2023)
- Investors on record: 7

## About

Based in Beijing, China, and established in 2018, Adamadle is a biotechnology company focusing on clinical development and pipeline expansion of oncology products. The company has the experience and ability to R&D of innovative drugs. It won the breakthrough therapy certification issued by the China Food and Drug Administration. In December 2023, the firm raised a series B funding for CNY 1 billion. The company has two subsidiaries, including Beijing Purunao Biotechnology Co., Ltd. and Beijing Anshi New Drug Technology Co., Ltd.

The company provides clinical development and pipeline expansion of anti-tumor drugs. The drugs include drug candidates in phase I clinical studies, and candidate compounds in preclinical and investigational new drug (IND) stages, in which c-Met target drug candidate is in the late clinical development stage.

## Funding rounds

- Series B, Dec 28, 2023, $141M — Bain Capital, IDG Capital, Cathay Capital, CS Capital, Yanchuang Capital
- Series A, Dec 9, 2021, $200M — Bain Capital, Vivo Capital, Primavera Capital Group

## Investors

- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- Primavera Capital Group (https://capitalatlas.ai/funds/primavera-capital-group) — Series A
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B
- Cathay Capital — Series B
- CS Capital — Series B
- Yanchuang Capital (https://capitalatlas.ai/funds/yanchuang-capital) — Series B